Digital Medicine Market

Digital medicine is worth USD 3.89 billion in 2025 on the Douglas Insights count, and USD 14.2 billion by 2035 at a 13.84% revenue CAGR. The digital medicine market covers software that treats, manages or monitors a diagnosed condition and is paid for per enrolled patient: virtual-first chronic care programmes, digital musculoskeletal therapy, prescription digital therapeutics and reimbursed remote monitoring. The arithmetic is simple: 9.42 million paid enrolments times an average USD 412.6 per enrolment-year equals USD 3.89 billion. Reimbursement is widening: Medicare extended its digital mental health treatment (DMHT) device codes G0552 to G0554 to digital therapy devices for attention deficit hyperactivity disorder (ADHD) from 1 January 2026, according to the Centers for Medicare and Medicaid Services (CMS) summary of the calendar year (CY) 2026 physician fee schedule final rule. The study belongs to our digital health coverage, and every number is built under the Douglas Insights research methodology.

How much does a health plan pay per digital medicine enrolment, and why do DiGA prices fall?

USD 412.6 per paid enrolment-year is the 2025 global average, but digital medicine prices split into three bands: about USD 600 in North America, USD 338 in Europe and under USD 200 in Asia Pacific. Musculoskeletal programmes sit at the top. German statutory prices reset sharply after year one.

Disclosed vendor revenue sets the top band. Hinge Health booked USD 587.9 million of 2025 revenue on 782,890 year-end members, per its fourth-quarter release filed with the SEC on 10 February 2026. Averaging opening and closing membership, Douglas Insights calculates roughly USD 894 of revenue per member-year for digital musculoskeletal care. Omada Health reported USD 260 million of 2025 revenue and 886,000 members, in its results of 5 March 2026, which works out near USD 357 per average member for cardiometabolic programmes.

Germany shows the opposite pressure on digital medicine pricing. The GKV-Spitzenverband DiGA report puts the average manufacturer price for a digital health application (DiGA) at EUR 544 in its first listed year, against an average negotiated price of EUR 227, a 59% cut. In 2025 statutory insurers spent more than EUR 170 million on 690,000 activations, about EUR 246 each.

Douglas Insights expects the global price per enrolment to rise only 1.1% a year, to USD 460.3 by 2035. US per-member fees climb with outcome guarantees and bundled GLP-1 support; European prices drift down as negotiated rates replace launch prices. The mix effect, with more low-priced Asian enrolments, holds the global average down.

Which digital medicine segment makes the money: chronic care programmes, musculoskeletal therapy or prescription apps?

Chronic condition management programmes make the most money, with 37.4% of 2025 digital medicine revenue, or USD 1.45 billion. Behavioural and mental health therapeutics grow fastest at 16.2% a year, because Medicare codes and FDA clearances turned prescription apps for depression, insomnia and ADHD into billable treatments.

Chronic condition management programmes hold USD 1.45 billion because diabetes, hypertension and weight programmes have the deepest US employer budgets; Teladoc Health alone counts 1.188 million chronic care enrollees. Digital musculoskeletal care earns USD 925.0 million from the highest price per member of any digital medicine segment, around USD 894. Behavioural and mental health therapeutics take USD 656.9 million and add the most growth, 16.2% a year, as new codes let clinicians bill for the devices.

Remote monitoring software and digital biomarkers account for USD 528.6 million, held back by billing that still pays mostly for the clinician minutes rather than the software. Medication adherence and companion apps are the smallest digital medicine segment at USD 322.6 million, since drug makers often give them away alongside a branded therapy, which caps the price at 11.7% growth.

By product the study splits revenue into Chronic condition management programmes, Digital musculoskeletal care, Behavioural and mental health therapeutics, Remote monitoring software and digital biomarkers, Medication adherence and companion apps. By therapy area the report covers diabetes, obesity, musculoskeletal pain, depression, insomnia, ADHD. By payer it splits revenue across employers, health plans, Medicare and statutory insurers, patients paying cash. By region it models North America, Europe, Asia Pacific, Latin America, Middle East and Africa.

Why are employers, Medicare and statutory insurers buying digital medicine enrolments faster?

Paid digital medicine enrolments grow 12.6% a year to 2035 in the Douglas Insights base case, from 9.42 million to 30.9 million. Four forces supply that volume: employer and health plan contracts, GLP-1 companion care, Medicare billing codes and European statutory reimbursement, each worth a measured share of the leg.

Employer and health plan contracting adds 5.1 points of the 12.6-point volume leg, the largest single contribution. Hinge Health finished 2025 with 2,830 clients, 25% more than a year earlier, and member growth of 47%, according to its 10 February 2026 release. The same release guides 2026 revenue to USD 732 million to USD 742 million, about 25% growth at the midpoint.

Companion care for glucagon-like peptide-1 (GLP-1) weight-loss drugs contributes 3.1 points. Omada Health says more than 150,000 members used its GLP-1 medication support in 2025, against 50,000 a year earlier, a threefold rise disclosed in its 5 March 2026 results. Douglas Insights counts these as new paid enrolments only when the programme is billed separately from the drug, so bundled drug-maker support adds nothing to the 9.42 million base. Omada Health also guides 2026 revenue to USD 312 million to USD 322 million, about 22% growth, which keeps that contribution credible.

Medicare and European reimbursement

Medicare billing adds 2.3 points. The CY 2026 final rule extends codes G0552, G0553 and G0554 to ADHD digital therapy devices furnished incident to behavioural health services, effective 1 January 2026, per the CMS rule summary. G0553 and G0554 carry national pricing, while G0552 is contractor priced. A billable code converts a prescription digital therapeutic from a free trial into a practice expense that is reimbursed, which is the step US prescription apps lacked before 2025. Douglas Insights values the behavioural segment at USD 656.9 million today for that reason, and expects it to reach USD 2.95 billion by 2035.

European statutory reimbursement and Asian programmes add the final 2.1 points. Germany listed 58 DiGA at the end of 2025 and recorded 1.6 million activations since September 2020, of which 690,000 came in 2025 alone, per the GKV-Spitzenverband report. Yearly activations therefore ran at roughly 43% of the five-year total in the latest year, the clearest sign that digital medicine prescribing in Europe is compounding. Together, 5.1 + 3.1 + 2.3 + 2.1 points equal the 12.6% volume leg, and the price leg of 1.1% sits on top of that to give the 13.84% revenue CAGR.

What hurdles cap digital medicine engagement and DiGA renewals?

Three hurdles remove 3.9 points from what would otherwise be a 16.5% digital medicine volume leg: member drop-off after the first months, statutory price resets and delistings, and payer demands for outcome evidence. Without them, Douglas Insights would model about 43.4 million enrolments in 2035 instead of 30.9 million.

Engagement decay removes 1.8 points. The chronic care book at Teladoc Health shrank 1% over the latest year to 1.188 million enrollees, showing that a mature digital medicine book can stall once the easiest employer accounts are signed. Programmes paid per engaged member lose revenue every time a patient stops logging readings, so churn hits volume and price at once.

Statutory price resets and delistings remove 0.9 points. Seven DiGA left the German directory in 2025 and 16 have left since the scheme opened, while six new ones joined, per the GKV-Spitzenverband. A 59% fall from the EUR 544 launch average to the EUR 227 negotiated average leaves small developers with too little margin to fund the trials needed for permanent listing.

Evidence scrutiny removes 1.2 points. Health plans now ask for claims-based savings before renewing a digital medicine contract, and statutory schemes ask for trial data. In Germany 16 applications were removed during their trial periods while 48 reached permanent status, so one in four trial outcomes, 16 of 64, ended in removal.

Who wins digital medicine contracts: Hinge Health, Omada, Teladoc or the prescription app makers?

Douglas Insights estimates Teladoc Health, Hinge Health and Omada Health hold about 41.6% of 2025 digital medicine revenue, based on disclosed programme revenue against the USD 3.89 billion total. Teladoc Health leads at an estimated 19.8%, ahead of Hinge Health at 15.1%.

The Teladoc figure, about USD 770 million, rests on the assumption that roughly half of its USD 1.58 billion Integrated Care segment comes from chronic condition programmes; the company does not split that figure. Hinge Health converted 47% member growth into 51% revenue growth. Omada Health, at an estimated 6.7%, ties its digital medicine position to GLP-1 support, where engaged members tripled to more than 150,000.

Sword Health competes with Hinge Health in musculoskeletal care and added a mental health product called Mind in 2025, when a funding round valued it at USD 4 billion. Otsuka announced FDA clearance for Rejoyn, a six-week app for major depressive disorder developed with Click Therapeutics, on 1 April 2024, per the Otsuka release. Big Health won clearance for SleepioRx in August 2024 and DaylightRx for generalised anxiety disorder on 4 September 2024, per its own announcement. Welldoc holds 8 FDA clearances for its BlueStar insulin software.

The Medicare ADHD code extension favours prescription app makers most: a vendor with an ADHD device can now be billed through practices rather than sold through pharmacy benefit deals. Douglas Insights puts the combined prescription app share at 3.2% of 2025 digital medicine revenue, rising toward 6.4% by 2035.

Where do digital medicine enrolments grow fastest beyond the US employer base?

North America leads digital medicine with USD 2.40 billion, or 61.8% of 2025 revenue, because US employers pay for programmes directly. Asia Pacific grows fastest at 17.6% a year, from USD 435.3 million, as insurers in Japan, China and Australia add app-based chronic care benefits.

North America reaches USD 8.12 billion by 2035, growing 12.95% a year, with the new Medicare codes extending demand from employers into seniors. Europe holds USD 843.4 million and grows 13.55%, carried by German DiGA spending of more than EUR 170 million a year and slower uptake elsewhere on the continent.

Asia Pacific is the fastest digital medicine region at 17.6% because its price per enrolment, about USD 196, lets public and private insurers enrol 2.22 million patients today at a fraction of US cost. Latin America adds USD 120.5 million, rising 15.1% a year as private health plans in Brazil and Mexico buy diabetes programmes.

Middle East and Africa is the wildcard: USD 85.5 million in 2025, but 16.36% growth to USD 389.0 million, driven by Gulf insurers paying about USD 312 per enrolment.

How do diabetes, obesity, insomnia and ADHD apps differ in digital medicine enrolment depth?

Diabetes and obesity supply about 52.7% of 2025 digital medicine enrolments in the Douglas Insights model, roughly 4.96 million patients, because programmes pair with glucose meters and GLP-1 drugs. Insomnia, depression and ADHD apps enrol fewer patients but last a fixed six to twelve weeks.

Course length changes the economics. Rejoyn runs six weeks and DaylightRx 90 days, so a prescription app earns one fee per course, while a cardiometabolic digital medicine programme bills every month the member stays engaged. Douglas Insights therefore counts a prescription course as one enrolment-year at its full course price, which keeps the 9.42 million figure comparable across therapy areas.

Musculoskeletal pain accounts for about 1.04 million enrolments, near 11.0% of the total, yet 23.8% of revenue because of the USD 894 price band.

Can GLP-1 companion programmes keep digital medicine members engaged past year one?

Yes, on current evidence: Omada Health tripled GLP-1 support members to more than 150,000 while lifting revenue 53%. Douglas Insights models GLP-1 companion care at 3.1 points of digital medicine volume growth, the second-largest driver, because drug payers want adherence data.

The risk sits in drug pricing. Software is not the issue. If GLP-1 list prices fall far enough that payers stop managing access tightly, the need for a paired digital medicine programme weakens. Douglas Insights holds the GLP-1 contribution at 3.1 points in the base case and cuts it to 1.4 points in the slower case.

What if Medicare uptake or GLP-1 support stalls: how far does the digital medicine 2035 value move?

USD 14.2 billion in 2035 is the base case, built on 12.6% volume growth and 1.1% price growth. A slower case with 8.9% volume and 0.2% price yields USD 9.30 billion; a faster case with 15.8% volume and 1.9% price reaches USD 20.3 billion, a 2.2-fold spread.

Volume has room to move. Adding one point to annual enrolment growth lifts the 2035 digital medicine total by about USD 1.31 billion; one extra point of price adds about USD 1.47 billion, because both legs compound on the same base. Our model in the slower case assumes practices rarely bill the new ADHD codes and GLP-1 support plateaus; the faster case assumes Medicare adds further conditions to the DMHT code family.

Other published forecasts put digital therapeutics growth at 21.83% to 27.8% a year. Our 13.84% sits well below that band because Douglas Insights excludes wearable hardware and general wellness apps, and because the two largest listed vendors guide 2026 growth to about 22% and 25%, already slowing from 2025.

Which rules decide whether a digital therapeutic gets a CMS code or a DiGA listing?

Two rule sets govern most digital medicine revenue: US FDA device clearance plus Medicare billing codes, and Germany’s DiGA fast-track, which has listed 58 applications. Together they shape roughly 83.5% of 2025 revenue, the North American and European share combined.

In the United States, a digital therapeutic first needs FDA clearance, as Rejoyn received in April 2024 and DaylightRx in September 2024, then a payment route. The CY 2026 rule summary requires that the billing practitioner incurs the cost of the DMHT device as a supply, which ties software sales to clinics rather than to patients directly.

Germany grants provisional listing for a trial year, then sets a negotiated price; 48 of the 58 listed DiGA held permanent status at the end of 2025, per the GKV-Spitzenverband report. Insurers argue that manufacturers setting their own first-year price creates financial risk, which signals more pressure on the EUR 544 launch average.

Douglas Exclusive: the Digital Medicine Reimbursement Atlas

The Digital Medicine Reimbursement Atlas is our model, built from 10 inputs. Those are 3 vendor disclosures (Hinge Health, Omada Health and Teladoc Health), 1 German statutory report, 1 Medicare rule and 5 regional assumptions. It is a modelled estimate, not an official register. It maps, region by region, who pays for a digital medicine enrolment, how much, and how many enrolments that buys.

The atlas finding: a price gap, not a volume gap. North America holds 42.6% of paid digital medicine enrolments but 61.8% of revenue, because a US enrolment earns 3.1 times an Asian one. Europe enrols 26.5% of patients for 21.7% of revenue, and its gap widens as negotiated DiGA prices replace launch prices.

Douglas Insights reads the atlas simply: Asia Pacific compounds on volume at 17.6%, while US growth depends on keeping USD 600 fees intact.

Receipts check: do 9.42 million paid enrolments at USD 412.6 really add up to the digital medicine market total?

Yes: 9.42 million paid enrolments times USD 412.6 equals USD 3.89 billion, the size of the Digital Medicine Market in 2025. Douglas Insights built the count across 5 regions, with direct data for 2 countries, the United States and Germany, from 10 inputs, of which 5 are sourced disclosures and 5 are regional price assumptions, then tested it against vendor revenue.

Cross-check one: Hinge Health, Omada Health and an estimated USD 770 million of Teladoc chronic care sum to about USD 1.62 billion, 41.6% of the total, consistent with a market where three listed vendors dominate US employer contracts. Cross-check two: German DiGA spending of more than EUR 170 million, converted at an assumed USD 1.13 per euro, gives about USD 192 million, 22.8% of the USD 843.4 million European figure.

Cross-check three: the 2035 figure of USD 14.2 billion equals 30.9 million enrolments at USD 460.3, within 0.1% of the compound result. Regions sum to the global total in 2025 exactly and within USD 0.2 million in 2035; segments sum within 0.1%. Sibling studies on the Telehealth Market, the AI in Mental Health Market and the Healthcare SaaS Solutions Market use the same per-enrolment logic where scopes overlap.

Sources

1. Centers for Medicare and Medicaid Services Medicare physician fee schedule final rule summary CY 2026 (MM14315) (2025)
2. Hinge Health / SEC Hinge Health fourth quarter and full year 2025 results (8-K exhibit 99.1) (2026)
3. Omada Health Omada Health fourth quarter and full year 2025 results (2026)
4. GKV-Spitzenverband DiGA-Bericht 2025 (2026)
5. Otsuka America Rejoyn FDA authorization (2024)
6. Big Health US FDA grants clearance for DaylightRx (2024)
7. SEC Teladoc Health Form 10-K FY2025 (2026)
8. SEC Omada Health Form 10-K FY2025 (2026)